On Tuesday, Valley National Bancorp (NYSE:VLY)’s shares inclined 0.99% to $10.17.
Valley National Bancorp (VLY) declared that it priced $100 million of its Subordinated Debentures due June 30, 2025 (the “Notes”) and 4,600,000 shares of its Fixed-to-Floating Rate Non-Cumulative Perpetual Preferred Stock, Series A (the “Preferred Stock”). The Notes have a fixed interest rate of 4.55% per annum, payable semi-annually, a 10 year term and were issued at a discount of 0.042% to par. The Preferred Stock will be issued at a public offering price of $25.00 per share. Dividends on the Preferred Stock will accrue and be payable quarterly in arrears, at a fixed rate per annum equal to 6.25% from the original issue date to, but not taking into account, June 30, 2025, and thereafter at a floating rate per annum equal to three-month LIBOR plus a spread of 3.85%.
Valley National Bancorp operates as the holding company for the Valley National Bank that provides commercial, retail, insurance, and wealth administration financial services products. The company operates through Commercial Lending, Consumer Lending, and Investment Administration segments. Its deposit products comprise non-interest bearing, savings, NOW, and money market deposits, in addition to certificates of deposit.
TiVo Inc. (NASDAQ:TIVO)’s shares dropped -0.19% to $10.66.
TiVo Inc. (TIVO) declared TiVo Online recently, a free new way for customers to find the programs they want to watch from their cable lineup or a wide variety of streaming services. TiVo Online delivers the power of TiVo’s search and discovery right on your PC or Mac®.1
TiVo Online eliminates the hassle of searching a variety of content providers and apps to identify what service offers your favorite show. At launch, TiVo subscribers can stream live and recorded TV when on their home network or launch titles with one click from supported programmers and streaming sites.2 An update planned for later this year will allow anyone who registers for a free TiVo account to enjoy the same highly personalized viewing experience accessible now to TiVo subscribers.
TiVo Inc. provides television software services and cloud-based software-as-a-service solutions that enable to view video content through various screens. It offers whole-home solutions that comprise 4-Tuner and 6-Tuner digital video recorders (DVRs)/gateways, non-DVR IP set-top boxes (STBs), and software to enable streaming to application on third-party devices, such as iOS and Android mobile phones and tablets through features, such as What to Watch Now, OnePass, integrated search, access to broadband video content, and TiVo online/mobile scheduling. As of January 31, 2015, the company had 5.5 million subscriptions to the TiVo service through its TiVo-owned and television service operators (MSO) businesses.
At the end of Tuesday’s trade, Webster Financial Corporation (NYSE:WBS)‘s shares surged 1.97% to $40.96.
Webster Financial Corporation (WBS) the holding company for Webster Bank, declared the release of its company-run 2015 capital stress test results as required by the Dodd-Frank Act. The stress test disclosure comprises results for both Webster Financial Corporation and Webster Bank, and can be found on Webster’s Investor Relations website under the heading “Presentations”
Information contained herein, counting Exhibit 99.1, shall not be deemed filed for the purposes of the Securities Exchange Act of 1934, nor shall such information and Exhibit be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such a filing.
Webster Financial Corporation operates as the bank and financial holding company for Webster Bank, National Association that provides financial services to individuals, families, and businesses in the United States. It operates through three segments: Commercial Banking, Community Banking, and Other.
Novartis AG (ADR) (NYSE:NVS), ended its Tuesday’s trading session with 1.06% gain, and closed at $101.17.
Novartis AG (ADR) (NVS) declared one-year study results from the MEASURE 2 pivotal Phase III study of investigational secukinumab in ankylosing spondylitis (AS). Data from the study demonstrated that about 74% of patients achieved clinically noteworthyimprovement in their symptoms after one year of treatment, as measured by ASAS20, a standard tool used to assess clinical improvement in AS1. Detailed study results were presented at the European League Against Rheumatism 2015 Annual Scientific Meeting (EULAR), in Rome, Italy . The safety and efficacy of investigational secukinumab are still under review for AS and market authorization has not been obtained.
In MEASURE 2, patients treated with investigational secukinumab 150 mg achieved significantly higher ASAS20 as compared to placebo at Week 16 (61.1% vs 28.4%; p1
Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. Its Pharmaceuticals division offers patented prescription medicines in various therapeutic areas, such as oncology, cardio-metabolic, immunology and dermatology, retina, respiratory, neuroscience, and established medicines.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
